Connect Biopharma Presents Results From Phase 3 52-Week Study In Patients With AD Conducted By Simcere Pharma At 2026 AAD Annual Meeting

Connect Biopharma Holdings Limited presented positive results from a Phase 3 52-week study of Rademikibart in patients with moderate-to-severe atopic dermatitis at the 2026 AAD Annual Meeting. The treatment achieved near-maximal efficacy responses in approximately 90% of patients and was well tolerated, with safety comparable to placebo. The study was conducted by Simcere Pharmaceutical Co., Ltd., and the company will host a conference call and webcast to discuss the findings.